TAKEAWAYS1. Controlled delivery begins with 1 agreed action.Measure the final amount through the selected pump, formula and bottle; do not borrow an instruction from another foam product.2. Foam is not a swallow-safety solution.AAP says OTC fluoride rinse should not be recommended below age 6 becaus Read More

TAKEAWAYS1. Build one gum-specific role.Use gum only when a chewable routine—not an instant spray or strip—is the correct consumer action.2. Review 3 sensory moments.Test first chew, post-coffee transition and end-of-chew finish; an appealing opening cannot rescue a waxy finish.3. Treat gum as a 2-p Read More

TAKEAWAYS1. Review 3 linked elements.Treat formula, foamer pump and final bottle as one project system; a good bulk liquid cannot prove finished-pack performance.2. Record 4 dispensing states.Compare first dispense after priming, normal repeated strokes, post-storage recovery and near-end-of-pack be Read More

TAKEAWAYS1. Set 3 linked specifications.Approve the HAp material basis, delivered amount, and delivery behavior together; no percentage can substitute for the other two.2. Name 2 different concentration bases.State both the formula-level addition basis and the dry-HAp-solids basis when the incoming Read More

TAKEAWAYSThree figures make a percentage auditable: record the raw-material addition, the agreed HAp-content basis, and the target or verified mg per finished tablet. An OEM quote that gives only “5%” or “10%” is incomplete.1–100 nm is terminology, not an automatic pass: ISO/TR 18401 uses that nanos Read More

TAKEAWAYSBelow 0.25 µg/mL signals an aqueous-formulation challenge: a pharmaceutical CoQ10 micelle paper reports very low water solubility for native CoQ10; this is not a mouthwash limit or a formula target.[2]2 redox forms need 1 clear assay basis: ubiquinone is the oxidized form and ubiquinol the Read More

TAKEAWAYSThree validation stages create a stronger release decision: FDA describes process design, process qualification, and continued process verification; adapt that lifecycle as a quality framework rather than treating one pilot as proof of reproducible output.[1]A dilution claim has at least 6 Read More

TAKEAWAYS0.045–0.1% is historical rinse context, not a spray instruction: FDA’s 2003 advance notice discussed that range for CPC mouthrinses with 72–77% chemically available CPC; it is not a current universal breath-spray dose or authorization.[1]A 0.3% spray study is evidence of difference, not a f Read More

TAKEAWAYSDose validation needs 2 outputs: compare the mean delivered amount against the target and review unit-to-unit variation; repeatable spray weight alone does not prove accuracy.[1]Freeze 4 test controls before comparing samples: formula version, final pack configuration, priming/rest state, a Read More

TAKEAWAYSTest enzyme systems as systems: oral-care lactoperoxidase examples combine an enzyme, thiocyanate, and a peroxide source. Request a finished-formula catalytic assay, not only protein content or a raw-material CoA.[1]Use 2 evidence layers for peptides: confirm the parent peptide with an appr Read More

TAKEAWAYS1. One line can contain two formats only when the jobs are different. A day spray may be briefed for an immediate, pocket-ready application; an evening lozenge may be briefed for a slower oral-solid routine. This is a design distinction—not a finished-product outcome claim.2. Two SKUs need Read More

TAKEAWAYS1 low-RDA target is a starting specification, not a finished consumer claim. Confirm the abrasivity of the actual formula with a defined method, laboratory, batch, and report.2 a whitening result and an abrasivity result answer different questions. Request separate evidence for cleaning or Read More